LOGIN  |  REGISTER
Compass Therapeutics

Veeva Systems to Present at Upcoming Investor Conference

January 13, 2025 | Last Trade: US$215.95 4.71 -2.13

PLEASANTON, Calif., Jan. 13, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced participation in the following investor conference:

  • 27th Annual Needham Growth Conference. Brian Van Wagener, CFO, and Paul Shawah, EVP Strategy, will present on Thursday, January 16, 2025, at 1:30 p.m. Eastern Time.

The above presentation will be webcast. Link to the live and archived webcast will be available on Veeva's investor relations website at https://ir.veeva.com.

About Veeva Systems

Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Veeva uses its ir.veeva.com website as a means of disclosing material non-public information, announcing upcoming investor conferences, and for complying with its disclosure obligations under Regulation FD. Accordingly, you should monitor Veeva's investor relations website in addition to following its press releases, SEC filings, and public conference calls and webcasts.

Investor Relations Contact:
Gunnar Hansen
Veeva Systems Inc.
267-460-5839
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact:
Maria Scurry
Veeva Systems Inc.
781-366-7617
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page